OBJECTIVES: Preeclampsia has  a high prevalence rate  and it’s the second leading cause of maternal mortality. In developing countries  a preeclampsia is the cause of 50 000 deaths each year. An effective method of preeclampsia prevention in accordance with WHO guidelines, is a prescription of antiplatelet drugs. METHODS: Analysis of consumed drugs for pregnant women, according to the real practice of the district hospital in Lviv region during 2014. Systematization of evidence data about the effectiveness of prevention and treatment of preeclampsia, which were published in the databases Cochrane, Pubmed, ClinicalTrials.gov RESULTS: The analysis of 112 medical records pregnant inpatients, who were hospitalized in September-December 2014, were conducted. For 42 (38%) patients were diagnosed the preeclampsia. For treatment intended antiplatelet drugs  for 17 patients that  only 40% were  taking  effective treatment. Other patients received  various vitamins and antioxidants that have not confirmed evidence-effectiveness. The analysis of databases showed that recent RCTs (2013) indicate that antiplatelet therapy reduced the risk of pre-eclampsia by 21%. In randomize studies found that reduced level of neonatal mortality on 16% and the frequency of children  born with low birth weight on 8%. In Ukraine, were registered  23 trade names of aspirin, including 11 from ukranian manufacturers. We calculated the costs of prevention during 5 months per patient (1 USD=22,3 UAH on 30.05.2015). Costs ranged from 3,10 USD to 15,5 USD. The best choice of affordable was aspirin in 75 mg with total costs 4,67 USD. CONCLUSIONS: We established that treatment with low doses of aspirin 75 mg / day in early pregnancy for women with  high risk of preeclampsia is an effective  prevention of preeclampsia. In Ukraine the patients have to pay out of pocket , than the necessary information support of  doctors in hospitals on  effective and affordable prevention of preeclampsia by antiplatelet schemes.